This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Shuiping Zhao, Central South University
ClinicalTrials.gov Identifier:
NCT01878604
First received: June 7, 2013
Last updated: February 17, 2017
Last verified: February 2017
  Purpose
Identify new or novel genes which may impact on cholesterol level, and establish the relationship between those gene mutations with atherosclerosis, as well as responses to lipid-lowering drugs.

Condition Intervention
Homozygous Familial Hypercholesterolemia Genetic: Gene analysis Other: Historical data of lipid-lowering drug administration Other: Historical data of plasma lipids, xanthoma changes

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: The Study of Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia

Resource links provided by NLM:


Further study details as provided by Shuiping Zhao, Central South University:

Primary Outcome Measures:
  • Number of LDLR Gene Mutations [ Time Frame: 1 year ]

    Number of gene mutations based on the sequencing results in terms of some known genes and suspected novel genes.

    c.796 G>C and c.1048 C>T in the LDLR gene c.1448 G>A and c.1720C>A in the LDLR gene c.2030 G >A and c.1257 C>A in the LDLR gene homozygous mutation c.605 T>C in the LDLR gene



Secondary Outcome Measures:
  • LDL-C Reduction Percentage [ Time Frame: pre-treatment and 6-13 years post treatment ]

    plasma LDL-C reduction percentage with lipid-lowering drugs from pre-treatment to the last time follow-up time point

    plasma LDL-C reduction percentage calculation: "plasma LDL-C at pre-treatment time point" minus "plasma LDL-C at the last time follow-up time point", and then compared with "plasma LDL-C at pre-treatment time point", namely "plasma LDL-C reduction percentage".



Biospecimen Retention:   Samples With DNA
Blood samples

Enrollment: 5
Study Start Date: October 2001
Study Completion Date: January 2015
Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Homozygous Familial Hypercholesterolemia
Gene Analysis for Homozygous Familial Hypercholesterolemia cases
Genetic: Gene analysis
Gene analysis
Other: Historical data of lipid-lowering drug administration
Collecting historical data of lipid-lowering drug administration
Other: Historical data of plasma lipids, xanthoma changes
Collecting historical data of plasma lipids and xanthoma changes

Detailed Description:

To better understand the genetics basis for LDL-C elevation and develop an optimized lipid-lowering strategy, we propose to do the following studies:

  1. To establish a China HoFH registry, and collect DNA and blood samples from all available family members of each proband (pedigrees);
  2. To detect gene mutations known to cause FH and identify family suitable for future whole genome sequencing aimed to identify novel genes controlling cholesterol levels.

3.To establish the relationship between types of gene mutations and lipid and atherosclerosis profile, as well as responses to lipid-lowering agents.

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Homozygous Familial Hypercholesterolemia
Criteria

Inclusion criteria:

Patients of any age and sex who meet clinical or genetic criteria for hoFH as follows:

  • Cutaneous xanthomata before the age of ten years
  • LDLC > 13 mmol/L before treatment or > 7.76 mmol/L despite treatment
  • Phenotypic features in keeping with HeFH in both parents

Exclusion criteria:

Inability of patient, or, if less than 18, a parent, to sign informed consent.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01878604

Locations
China, Hunan
Cardiology department of 2nd Xiangya Hospital
Changsha, Hunan, China, 410011
Sponsors and Collaborators
Central South University
Investigators
Principal Investigator: Shuiping Zhao, Doctor Central South University
  More Information

Responsible Party: Shuiping Zhao, Chief of Cardiology Department, 2nd Xiangya Hospital, Central South University
ClinicalTrials.gov Identifier: NCT01878604     History of Changes
Other Study ID Numbers: MISP50469
Study First Received: June 7, 2013
Results First Received: October 31, 2016
Last Updated: February 17, 2017

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipoproteinemia Type II
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Hyperlipoproteinemias
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents

ClinicalTrials.gov processed this record on August 18, 2017